Oncologist’s opinion on the drugs for review capmatinib, tepotinib, crizotinib, and cabozantinib.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.